- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT03094819
PROTECT2: Diabetes Care - Eye Exam
The PROTECT2 pilot study is a single cohort prospective study to gather pilot data and finalize operational details of the main study.
The PROTECT2 main study is a prospective randomized controlled multi-center three group clinical trial. The primary endpoint is the percentage of participants in each study group obtaining a qualified eye examination within 12 months of their enrollment in the study.
Studieoversikt
Status
Intervensjon / Behandling
Detaljert beskrivelse
The primary objective of this study is to compare the qualified eye examination rate in two groups of patients with diabetes receiving a new intervention, with the rate in a control group of patients with diabetes receiving usual care only.
Secondary objectives are to:
- Improve our understanding of the barriers to obtaining eye examinations;
- Evaluate the communication between eye care providers (ECP) and referring primary care providers (PCP), as determined by rates of follow-up reports sent and received;
- Characterize eye examinations provided to patients with diabetes;
- Explore the relationships between systemic variables known to affect the severity of diabetic retinopathy and the patient's risk of vision-threatening diabetic retinopathy.
Design and Primary Endpoint
- The pilot study is a single cohort prospective study to gather pilot data and finalize operational details of the main study.
- The main study is a prospective randomized controlled multi-center three group clinical trial. The primary endpoint is the percentage of participants in each study group obtaining a qualified eye examination within 12 months of their enrollment in the study.
Interventions and Duration
Eligible patients will be randomized to one of three groups in a 1:1:2 ratio.
- Group 1. Participants randomized to Group 1 will be the control group. They will be observed while they receive usual eye care without any study intervention.
- Financial Incentive. Participants randomized to the Financial Incentive group will be offered a financial incentive in conjunction with their usual eye care. They will receive usual care and a $25 payment if they obtain a confirmed eye examination.
- Retinal Care DR Service. Participants randomized to the Retinal Care DR Service group will receive: (1) point of care risk assessment for vision- threatening diabetic retinopathy, (2) retinal specialist interpretation of their risk assessment data, and (3) care coordination designed to improve the eye examination rate for patients with diabetes at increased risk for vision- threatening diabetic retinopathy.
All participants, regardless of their group, will be in the study for about one year.
Sample Size and Population Patients meeting the inclusion and exclusion criteria will be recruited at up to four (4) study sites until the sample size of 4,500 participants is enrolled. This includes up to 500 patients at each site in the pilot study, and weighted randomization in the main study to ensure enrollment of approximately 500 patients in the Retinal Care DR Service group at each site to evaluate the operational characteristics of the Retinal Care DR Service in populations representative of those anticipated in commercial use.
Studietype
Registrering (Forventet)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiesteder
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Forente stater, 73104-5065
- Dean McGee Eye Institute
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Diagnosed diabetes using the criteria documented in the 2016 Physician Quality Reporting System (PQRS) Measure Specifications Manual for Claims and Registry Reporting of Individual Measures.
- 18 through 75 years of age
- Have a PCP appointment scheduled within 90 days of the date of medical record review.
Exclusion Criteria:
- Patients not diagnosed with diabetes
- History of photosensitive epilepsy
- Inability or unwillingness of the participant to give verbal or written informed consent.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Helsetjenesteforskning
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Trippel
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Ingen inngripen: Group 1
Participants randomized to Group 1 will be the control group.
They will be observed while they receive usual eye care without any study intervention.
|
|
Eksperimentell: Financial Incentive
Participants randomized to the Financial Incentive group will be offered a financial incentive in conjunction with their usual eye care.
They will receive usual care and a $25 payment if they obtain a confirmed eye examination.
|
Participants will receive usual care and a $25 payment if they obtain a confirmed eye examination.
|
Eksperimentell: Retinal Care DR
Participants randomized to the Retinal Care DR Service group will receive: (1) point of care risk assessment for vision-threatening diabetic retinopathy, (2) retinal specialist interpretation of their risk assessment data, and (3) care coordination designed to improve the eye examination rate for patients with diabetes at increased risk for vision-threatening diabetic retinopathy.
|
Participants will receive: (1) point of care risk assessment for vision- threatening diabetic retinopathy, (2) retinal specialist interpretation of their risk assessment data, and (3) care coordination designed to improve the eye examination rate for patients with diabetes at increased risk for vision- threatening diabetic retinopathy.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Qualified eye examination rate
Tidsramme: 12 months
|
Percent of participants in each study group obtaining a qualified eye examination.
|
12 months
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
PCP report rate
Tidsramme: 12 months
|
Percent of eye examinations with a follow-up report sent to the PCP.
|
12 months
|
PCP medical record rate
Tidsramme: 12 months
|
Percent of eye examinations with a follow-up report sent to the PCP, where the results of the follow-up report are documented in the PCP medical record.
|
12 months
|
Eye examination barriers
Tidsramme: 12 months
|
Descriptive analysis of barriers to obtaining an eye examination.
|
12 months
|
Increased risk group eye examination rate
Tidsramme: 12 months
|
Percent of participants at increased risk for vision-threatening diabetic retinopathy who are subsequently seen by an eye care provider.
|
12 months
|
Eye examination findings
Tidsramme: 12 months
|
Descriptive analysis of eye examination findings for participants at increased risk for vision-threatening diabetic retinopathy.
|
12 months
|
Eye examination components
Tidsramme: 12 months
|
Descriptive analysis of eye examination components for participants at increased risk for vision-threatening diabetic retinopathy.
|
12 months
|
Eye care costs
Tidsramme: 12 months
|
Numerical analysis of eye care costs using provider reported and claims data.
|
12 months
|
Risk correlations
Tidsramme: 12 months
|
Correlation analysis of systemic variables known to affect the severity of diabetic retinopathy and retinal specialist interpretation of participant's risk assessment data.
|
12 months
|
Participant perceptions
Tidsramme: 12 months
|
Descriptive analysis of participant perceptions of the Retinal Care DR Service.
|
12 months
|
Samarbeidspartnere og etterforskere
Sponsor
Samarbeidspartnere
Etterforskere
- Hovedetterforsker: Ronald M Kingsley, MD, Dean McGee Eye Institute / University of Oklahoma Health Sciences Center
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Forventet)
Studiet fullført (Forventet)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 09-PLN-001
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Diabetisk retinopati
-
Assiut UniversityUkjentom Vitreomacular Interface Abnormalities in Diabetic Retinopathy
Kliniske studier på Financial Incentive
-
University of GeorgiaMcMaster University; University of KentuckyRekruttering
-
Indiana Institute for Medical ResearchGenentech, Inc.; Regenstrief Institute, Inc.; Richard L. Roudebush VA Medical...Fullført
-
University of PennsylvaniaFullførtLeddgikt, revmatoid | Leddgikt, psoriasisForente stater
-
Chestnut Health SystemsNational Institute on Alcohol Abuse and Alcoholism (NIAAA)Fullført
-
Yonsei UniversityFullførtCerebral pareseKorea, Republikken
-
McMaster UniversityMcMaster Surgical AssociatesFullførtLungeneoplasmer | Godartet lungesykdomCanada
-
Singapore National Eye CentreFullført
-
Milton S. Hershey Medical CenterAvsluttetPostoperativ respiratorisk komplikasjonForente stater
-
Riphah International UniversityFullførtHjerneslag (CVA) eller TIAPakistan
-
Cliniques universitaires Saint-Luc- Université...Fullført